Fda announced 2 revisions concerning the variety of dosages per vial available for the Moderna COVID-19 Vaccine. Press Release/ Public Declaration 03/26/2021 The FDA problems an emergency situation usage authorization (EUA) to a business for the SARS-Co, V-2 NGS Assay and offers a customer update on typical questions about COVID-19 vaccines.
Customer Information 03/17/2021 FDA leadership will take part in the House Subcommittee on Oversight and Examinations of the Committee on Energy and Commerce hearing entitled, "Blazing a trail Forward: Biden Administration Actions to Increase COVID-19 Vaccinations." View livestream and written testimony Occasion 03/05/2021 FDA's Office of Minority Health and Health Equity discusses the firm's efforts to stop deceitful items from reaching our markets, specifically those claiming to avoid, treat, or cure COVID-19.
Post 03/02/2021 The FDA issues Voices on protecting consumers versus COVID-19 vaccine scams and issues a caution letter to a company offering unapproved items with deceptive COVID-19 claims. News Release/ Public Declaration 02/27/2021 Today, the U.S. Fda issued an emergency usage authorization (EUA) for the 3rd vaccine for the prevention of coronavirus illness 2019 (COVID-19) triggered by severe acute respiratory syndrome coronavirus 2 (SARS-Co, V-2).
COVID-19 Vaccine, the FDA has informed the sponsor that it will rapidly pursue completion and issuance of an emergency situation use permission. News Release/ Public Statement 02/26/2021 Today, the FDA added brand-new gadgets to the gadget discontinuance list, including sterilization products and oxygen conservers. COVID-19 Update 02/26/2021 The Vaccines and Related Biological Products Advisory Committee will satisfy in open session to go over Emergency situation Usage Permission (EUA) of the Janssen Biotech Inc.
. View livestream Occasion 02/25/2021 Today, the FDA announced that it is permitting pure frozen vials of the Pfizer-Bio, NTech COVID-19 Vaccine to be carried and saved at conventional temperature levels typically discovered in pharmaceutical freezers for a period of approximately two weeks. Press Release/ Public Declaration 02/23/2021 FDA released guidances for medical item designers to attend to the development and possible future emergence of variations of SARS-Co, V-2.